Prevention of Diabetic Nephropathy by Sulforaphane: Possible Role of Nrf2 Upregulation and Activation
Figure 1
SFN prevented diabetes-induced renal structural changes and fibrosis. Diabetic and age-matched mice were treated with SFN at 0.5 mg/kg daily for five days in each week for 3 months, and then some were used to perform the experimental measurements at the end of 3-month SFN treatment (3-month time-point). Some of these diabetic and age-matched control mice with and without 3-month SFN treatment were kept for additional 3 months without further SFN treatment and then were sacrificed for study (6-month time-point). To examine renal morphology sections were stained with hematoxylin and eosin (a). Periodic acid-Schiff staining was used to examine glycogen accumulation (b). Bar = 100 μM. Western blotting assay was performed for measuring fibrosis by TGF-β1 and CTGF protein expression (c). Data were presented as means ± SD ( at least) *P < 0.05 versus control; (#P < 0.05 versus DM group).
